Nano LIFE, published by World Scientific Publishing Company, is a multidisciplinary journal that delves into the dynamic fields of bioengineering, biomedical engineering, and pharmaceutical science, providing a platform for researchers to disseminate their cutting-edge findings. With an ISSN of 1793-9844 and e-ISSN 1793-9852, this journal emphasizes the significance of nanoscale research in healthcare and technology, positioning itself as a vital resource for professionals and academics alike. Although currently categorized in the Q4 quartile for multiple scientific disciplines in 2023, its unique focus on the intersection of nanotechnology and life sciences aims to elevate the discourse in these rapidly evolving sectors. Researchers can anticipate publishing innovative methodologies and results, contributing to the overall understanding and application of nanotechnology in medicine. Located in Singapore, Nano LIFE not only serves the global research community but also reflects the growing interest in nanotechnology across diverse fields.

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS is an esteemed academic journal published by BEGELL HOUSE INC, focusing on the innovative field of drug delivery systems and therapeutic carriers. With an ISSN of 0743-4863 and E-ISSN 2162-660X, this journal serves as a pivotal resource for researchers, professionals, and students engaged in pharmaceutical sciences and pharmacology. Spanning from 1984 to 2024, it has sustained its relevance in an evolving landscape, holding a commendable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science, as well as a Q3 ranking in Pharmacology for 2023. The journal is well-regarded for its critical and comprehensive reviews that enhance understanding and drive advancements in therapeutic applications. Access options are variable, providing insights into contemporary practices and innovations that shape drug delivery strategies. With a strong emphasis on interdisciplinary approaches, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS not only fosters scholarly dialogue but also propels forward the critical field of therapeutic delivery, making it a valuable asset for anyone looking to deepen their knowledge and influence within this dynamic area of study.

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Progress in Biomedical Engineering, published by IOP Publishing Ltd, is a premier open-access journal that serves as a vital platform for the dissemination of innovative research in the field of biomedical engineering. With an impressive Q1 classification in the Biomedical Engineering category for 2023, this journal has established itself as a significant contributor to the advancement of engineering solutions that improve healthcare outcomes. Recognized for its high-quality and impactful publications, it ranks 51st out of 303 in its field on Scopus, placing it in the 83rd percentile. The journal aims to foster interdisciplinary collaboration and introduce pioneering methodologies and technologies that bridge the gap between engineering and medicine. By providing a pathway for rapid communication of fundamental and applied research, Progress in Biomedical Engineering is dedicated to shaping the future of healthcare technology. Access to its content ensures that researchers, professionals, and students remain at the forefront of biomedical innovation.

Current Cancer Therapy Reviews, an esteemed journal published by Bentham Science Publishers Ltd, serves as a critical resource in the fields of cancer research, molecular medicine, and oncology. With an ISSN of 1573-3947 and an E-ISSN of 1875-6301, this journal provides a platform for the rapid dissemination of reviews that articulate the latest advancements and therapeutic strategies in cancer treatment. Although it currently holds a Q4 classification in its respective categories, the journal's commitment to quality scholarship is evident in its engagement with an expansive range of topics impacting cancer care. Operating from the United Arab Emirates since its inception in 2006, it is an essential tool for researchers, clinicians, and students aiming to stay abreast of the evolving landscape of cancer therapy. The journal emphasizes open access to knowledge, fostering a collaborative environment for innovative research. For those looking to deepen their understanding of contemporary cancer therapies, Current Cancer Therapy Reviews is a valuable addition to their academic resources.

Nanomedicine Journal, published by Mashhad University of Medical Sciences, serves as a vital platform for research and developments in the dynamic field of nanotechnology applied to medicine. With an ISSN of 2322-3049 and an E-ISSN of 2322-5904, this Open Access journal, operational since 2013, makes cutting-edge research freely accessible to encourage collaborative efforts in this rapidly evolving domain. The journal navigates various areas, including bioengineering, biomedical engineering, materials science, and pharmacology, holding prestigious rankings in categories relevant to these fields. The 2023 Scopus Rankings reveal its significant standing within the scientific community, particularly with a 76th percentile in general medicine. By bridging the gap between laboratory technologies and clinical applications, the Nanomedicine Journal aims to empower researchers, professionals, and students alike to contribute to the innovative landscape of nanomedicine. With a convergence period extending from 2019 to 2024 and an established reputation, this journal is essential for those pursuing advancements in therapeutic solutions and diagnostics through nanotechnology.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

BME Frontiers, published by the American Association for the Advancement of Science, is an innovative open-access journal dedicated to the burgeoning field of Biomedical Engineering. Since its establishment in 2020, this journal has aimed to bridge the gap between cutting-edge research and practical application, promoting advancements in biomedical technologies, medical devices, and healthcare solutions. Boasting impressive rankings within Scopus—64th among 398 in Medicine (miscellaneous) and 81st among 303 in Biomedical Engineering—BME Frontiers stands out as a significant contributor to scholarly communication, offering rich insights for researchers, professionals, and students alike. With consistent publication projected through 2024, the journal serves as an essential platform for disseminating high-quality research that can drive innovation and inspire new approaches in the healthcare sector.

ACS Biomaterials Science & Engineering, published by the American Chemical Society, serves as a premier platform for the latest advancements and research in the fields of biomaterials and biomedical engineering. With an impressive impact factor and a strong reputation reflected in its ranking—Q2 in Biomaterials and Q1 in Biomedical Engineering—the journal attracts a diverse and engaged readership. Since its inception in 2015, it has aimed to foster innovation by publishing high-quality research articles, reviews, and perspectives on the synthesis, characterization, and application of biomaterials. Researchers and professionals benefit from the journal's rigorous peer-review process and its focus on translational science, making it essential for those looking to stay at the forefront of biomaterials research. Located in Washington, DC, USA, the journal plays a pivotal role in connecting academic and industrial sectors, ultimately driving advancements that impact biomedicine and related fields.

Artificial Cells Nanomedicine and Biotechnology is a prestigious peer-reviewed journal published by TAYLOR & FRANCIS LTD, specializing in the rapidly evolving fields of biomedical engineering, biotechnology, and nanomedicine. Established in 2013 and operating under an open-access model since 2019, the journal aims to bridge the gap between fundamental science and real-world medical applications, showcasing cutting-edge research that advances our understanding of artificial cells and their biotechnological applications. With an impressive impact factor and ranking in the Q2 quartile across various categories, including Biomedical Engineering, Medicine, and Pharmaceutical Sciences, the journal is a leading platform for innovative studies that contribute significantly to the realm of healthcare and therapeutic development. Researchers, professionals, and students alike will find invaluable insights and advancements within its pages, positioning it as a vital resource for those dedicated to pushing the boundaries of science and improving patient outcomes.